Devonian Health Group Inc
🇨🇦XTSX.GSDCanadaHealthcare
PriceCA$8.950.00 (0%)
Latest anomalies
Neutral 0 detected in the last 120 days
- High: 11
- Medium: 5
- Low: 0
Asset turnover: a sudden spike above its trailing quarter average
Book to market ratio: a sudden drop below its trailing quarter average
Fixed asset turnover: a sudden spike above its trailing quarter average
Inventory turnover: a sudden spike above its trailing quarter average
Net margin: collapsed against the prior period
Free with a Finzer account.
Profile
- Healthcare
- Biotechnology
- Canada
Identity
- Exchange
- TSX Venture Exchange . XTSX
- Type
- Stock
- ISIN
- CA2518341078
- CUSIP
- 251834107
Company
- Employees
- 6
- Headquarters
- Québec, Canada
- Website
- https://groupedevonian.com
Market
- Shares outstanding
- 2.8M
- Market cap
- CA$1.33B
Highlights
No high and low reported for today's session.
- Market cap
- CA$1.33B
- EPS LTM
- -CA$0.03calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- -307.66calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- CA$31.18M+207.66%up year on year
- Net income
- -CA$4.31M-25.34%down year on year
- Gross margin
- 33.55%-0.05%down year on year
- Free cash flow
- CA$8.41M+538.29%up year on year
Latest news
News is not sourced for this exchange.
Business summary
Devonian Health Group Inc is a company in the healthcare sector, listed on TSX Venture Exchange (Canada) under the ticker GSD. Its market capitalisation is CA$1.33B, from 2.8M shares outstanding, as of . Across the 246 trading sessions to the shares traded between CA$0.14 and CA$14.99, and the last close of CA$8.95 sits 59% of the way up that range. The company is headquartered in Québec, Canada, and employs about 6 people.
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops Pantoprazole Magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; Dexlansoprazole; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the Purgenesis name. Devonian Health Group Inc. is headquartered in Québec, Canada.